ReviewCureus2026
Optimizing Management of Morton's Neuroma: Extracorporeal Shock Wave Therapy in Clinical Practice.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morton's neuroma (MN) is frequently refractory to conventional conservative therapies, and surgical excision carries the risk of recurrent pain. While extracorporeal shock wave therapy (ESWT) has emerged as a potential non-invasive intervention for MN, a standardized clinical protocol for its application remains to be established. This review aims to elucidate the physiological validity of ESWT for MN and propose an optimized clinical protocol. Existing randomized controlled trials of ESWT for MN were analyzed, and findings from other entrapment neuropathies were extrapolated to critically appraise interventional factors influencing therapeutic outcomes. ESWT exerts a biphasic effect: immediate analgesia via the degeneration of free nerve endings, and radical pathophysiological improvement through the promotion of neovascularization and tissue repair. The present analysis suggests that the use of local anesthesia may inhibit mechanotransduction, potentially reducing success rates. Furthermore, considering the dynamics of growth factors involved in tissue regeneration, multiple sessions at one-week intervals are more rational than a single application. Optimizing ESWT through repetitive sessions without anesthesia at the maximum tolerable energy flux density may maximize therapeutic efficacy. ESWT is expected to become an integral, minimally invasive standard therapy that precludes the necessity for surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.